Back to Journals » Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy » Volume 11

Statin on insulin and adiponectin levels: true or false prophecy?

Authors Jonnalagadda VG, Shaik A

Received 26 December 2017

Accepted for publication 28 December 2017

Published 12 April 2018 Volume 2018:11 Pages 131—132


Checked for plagiarism Yes

Editor who approved publication: Professor Ming-Hui Zou

Venu Gopal Jonnalagadda,1 Afsar Shaik2

1Department of Pharmacology & Toxicology, National Institute of Pharmaceutical Education and Research, Bhangagarh, Guwahati, Assam, India; 2Department of Pharmacology, Narayana Pharmacy College, Chinthareddy Palem, Nellore, Andhra Pradesh, India

We read the article “Effect of different doses of statins on the development of type 2 diabetes mellitus in patients with myocardial infarction” by Gruzdeva et al1 with interest. The authors conducted a prospective cohort study on patients with diagnosed myocardial infarction who were on different doses of atorvastatin, ie, 20 mg/d or 40 mg/d, for new onset of diabetes for a duration of 12 months.

Authors’ reply

Evgenya Uchasova, Olga Gruzdeva

Federal State Budgetary Institution, Research Institute for Complex Issues of Cardiovascular Diseases, Kemerovo, Russian Federation

We would like to thank Venu Gopal Jonnalagadda and Afsar Shaik for the letter in response to our article.1 Yes, indeed in our study, statins at a dose of 20 and 40 mg/mL, at 20 mg/d atorvastatin, were observed to improve the sensitivity to insulin and eliminate adipokine imbalance and ghrelin deficiency. At a dose of 40 mg/d, atorvastatin showed increased negative effects, such as a reduction in insulin secretion, hyperglycemia, impaired glucose tolerance, high levels of leptin, ghrelin deficiency, and manifestation of type 2 diabetes mellitus. Statins at a dose of 80 mg/mL were not included in this work; however, at this dose in this study, we observed a decrease in levels of adiponectin and insulin.1

View the original paper by Gruzdeva and colleagues.

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]